Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.gastro.2023.09.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Asia Pac J Clin Oncol
September 2025
Roche Products India Pvt. Ltd, Mumbai, India.
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.
Efficacy and Safety of Different Doses of Bevacizumab Combined with Atezolizumab in Unresectable Hepatocellular Carcinoma.
J Hepatocell Carcinoma
August 2025
Department of Liver Transplantation, The First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Purpose: To evaluate the efficacy and safety of different doses of bevacizumab combined with atezolizumab in patients with unresectable hepatocellular carcinoma.
Methods: A retrospective analysis was conducted on clinical data from patients receiving Atezo-Bev therapy at our institution. Patients were stratified into standard-dose (SD) and low-dose (LD) groups based on bevacizumab dosage.
Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018-2022.
Cancer Med
September 2025
Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
Background: The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab-paclitaxel (GnP), and single-agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival.
Materials And Methods: Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first-line mFFX, GnP or GEM were extracted from the population-based Queensland Oncology Repository.
Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma.
Oncogene
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The underlying mechanisms leading to ferroptosis hypersensitivity are unknown.
View Article and Find Full Text PDFLiver Transplant for Intrahepatic Cholangiocarcinoma: Current Evidence and Clinical Practice Recommendations.
J Gastrointest Surg
September 2025
Department of Surgery, Massachusetts General Hospital, Boston, MA. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) incidence is increasing globally and is associated with poor prognosis. Surgical resection remains the main curative treatment. However, many patients present with unresectable disease or underlying liver dysfunction, precluding resection.
View Article and Find Full Text PDF